<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01100034</url>
  </required_header>
  <id_info>
    <org_study_id>0881X1-4654</org_study_id>
    <secondary_id>B1801035</secondary_id>
    <nct_id>NCT01100034</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis</brief_title>
  <acronym>PURPOSE</acronym>
  <official_title>A Long-term, Prospective, Observational Cohort Study Of The Safety And Effectiveness Of Etanercept In The Treatment Of Paediatric Psoriasis Patients In A Naturalistic Setting: A Post-authorization Safety Study (Pass)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psoriasis is a chronic, often severe, autoimmune condition that affects approximately 2% of
      the world's population. The epidemiology of pediatric psoriasis has not been well documented
      and no treatment guidelines exist for pediatric psoriasis.

      Etanercept is a biologic drug and has been licensed for the treatment of chronic severe
      plaque psoriasis in children and adolescents (8-17 years of age) who are inadequately
      controlled by or are intolerant to, other systemic therapies or phototherapies. Although the
      long-term safety and efficacy of etanercept in children with juvenile idiopathic arthritis
      (JIA) has been studied and the short-term safety profile of etanercept in both JIA and
      pediatric psoriasis appears similar, there is limited data available about the long-term
      effects of etanercept in pediatric psoriasis, especially with respect to malignancy. The aim
      of this study is to assess the safety and effectiveness of etanercept for the treatment of
      pediatric psoriasis in Europe. Patients aged 4-17 with plaque psoriasis diagnosed by a
      dermatologist will be invited to participate in the registry only after a clinical decision
      has been made to prescribe etanercept. The safety of the drug and how well the drug works
      will be evaluated during the follow-up period. The follow-up period will last 5 years and
      patients will be followed up every 3 months for the first 2 years and every 6 months for the
      next 3 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-probability sample
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2010</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of SAEs including serious infections and malignancy</measure>
    <time_frame>Five year follow-up. Follow-up every 3 months for the first 2 years and 6 monthly for the next 3 yr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness or lack of effectiveness will be inferred from the number of 24 week courses the patient completes</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">72</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>pediatric patients with plaque psoriasis on etanercept</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Expected duration of 24 weeks as one course</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        dermatology clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  17 years of age or younger

          -  Diagnosed with plaque psoriasis by a dermatologist.

          -  Prior to enrollment, there must be a clinical decision to initiate etanercept for the
             treatment of plaque psoriasis and etanercept must then be initiated.

          -  Actively being treated with etanercept, regardless of length of treatment prior to
             enrollment

          -  Willing to provide written informed consent

        Exclusion Criteria:

          -  Prior therapy with etanercept or other biologic agent

          -  History of malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy / Service de Dermatologie</name>
      <address>
        <city>Argenteuil Cedex</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Trousseau, Service de Dermatologie</name>
      <address>
        <city>Chambray-lès-Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik fuer Dermatologie, Allergologie und Venerologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum der TU Dresden Carl Gustav CarusKlinik</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hartmmannstrasse 14 Erlangen 91052</name>
      <address>
        <city>Erlangen</city>
        <zip>91052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hufelandstr. 55 Essen 45147</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J W Goethe Universitaet Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kath. Kinderkrankenhaus Wilhelmstift</name>
      <address>
        <city>Hamburg</city>
        <zip>22149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Koeln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderklinik der Johannes-Gutenberg Universitat Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Sankt Augustin GmbH</name>
      <address>
        <city>Sankt Augustin</city>
        <zip>53757</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Athens Andreas Syngros Hospital Athens, Greece</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Skin and Venereal Diseases</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54644</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heim Pal Children's Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Dermatologia ARNAS</name>
      <address>
        <city>Palermo</city>
        <zip>90100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cattedra Policlinico Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Alfredo Fiorini</name>
      <address>
        <city>Terracina</city>
        <zip>04019</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St Radbound</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-028</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Cruz y San Pablo</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Tauli</name>
      <address>
        <city>Barcelona</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Denmark</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=0881X1-4654&amp;StudyName=Study%20Evaluating%20the%20Safety%20and%20Effectiveness%20of%20Etanercept%20for%20the%20Treatment%20of%20Pediatric%20Psoriasis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2010</study_first_submitted>
  <study_first_submitted_qc>April 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2010</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric psoriasis</keyword>
  <keyword>etanercept</keyword>
  <keyword>PASS</keyword>
  <keyword>safety</keyword>
  <keyword>effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

